Global biopharmaceutical company Biocon Ltd. announced Sept. 10 the opening of its first U.S. manufacturing facility in Cranbury by its wholly owned subsidiary, Biocon Generics Inc.
Gov. Phil Murphy, Biocon’s Chairperson Kiran Mazumdar-Shaw, and dignitaries, customers, partners, and industry leaders were in attendance.
Biocon acquired the Oral Solid Dosage facility from Eywa Pharma Inc. in 2023 and has since invested more than $30 million to establish a plant with an annual production capacity of 2 billion tablets. A few products have already been commercialized from the site, with several more in the pipeline. This investment helps Biocon diversify its manufacturing base, strengthen its supply chain and accelerate the expansion of its global footprint.
The Cranbury facility represents a strategic advancement for the company’s U.S. operations, enabling faster access to essential therapies, enhanced supply reliability and a stronger connection with partners and health-care providers, ultimately benefitting patients across the United States.
Biocon joins a burgeoning industrial sector in New Jersey. Business advocacy group Choose New Jersey said the state has the highest concentration of scientists and engineers per square mile in the United States. New Jersey is home to eight of the top 10 global biopharmaceutical companies, eight of the top 10 R&D companies, and more than 5,600 life-sciences establishments.
“Biocon’s first U.S. FDA-approved formulations facility in New Jersey marks a new chapter in our journey of global expansion,” said Mazumdar-Shaw. “More than a milestone, it is a reaffirmation of our purpose to serve patients wherever they are. This facility reflects our long-term commitment to deeper engagement with health-care providers, innovators, and communities to build a healthier and equitable future.”
Siddharth Mittal, chief executive officer and managing director, Biocon Ltd, commented, “This strategic investment brings us closer to patients, health-care providers, and partners in this important market. The proximity allows us to deliver our vertically integrated, high-quality medicines more efficiently to patients across the United States and other markets, ensuring supply chain resilience and enabling us to advance our mission of expanding access to affordable therapies worldwide.”
“We are incredibly grateful that Biocon has decided to open its first U.S. manufacturing facility in the Garden State,” said Murphy. “This state-of-the-art facility marks a significant moment in Biocon’s global expansion and reinforces New Jersey’s reputation as the medicine chest to the world.”
Biocon Ltd. is a biopharmaceutical company focused on enhancing affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune diseases. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets, as well as generic formulations in the U.S. and Europe.
